Payment overview · 2025
General Payments
$1,176.57
65 reported records · 23 companies
Healthcare provider profile · identity verified
Marta Heshelman
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BLOOMINGTON, IN · NPI 1730540592
Verified facts
What the public records show
CMS Open Payments records show Marta Heshelman received $1,176.57 in general payments during 2025 across 65 reported records.
Novo Nordisk Inc accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $184.37 | 15.7% | 15 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $158.07 | 13.4% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $143.42 | 12.2% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.96 | 7.4% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.63 | 5.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.31 | 4.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.76 | 4.3% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.59 | 4.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $46.20 | 3.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $42.70 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.08 | 3.1% | 2 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $32.53 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.60 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.87 | 2.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $24.79 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.23 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.06 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.93 | 1.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $18.52 | 1.6% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $16.59 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.55 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.63 | 1.2% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $14.18 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,176.57 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $158.07 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $143.42 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.40 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $110.50 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.96 | 4 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $63.63 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 2 LAPIFUSE Normalized: ortholoc 2 lapifuse |
Device | Stryker Corporation | $46.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.19 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 34 |
| Lisinopril | Lisinopril | 122 | 25 |
| Omeprazole | Omeprazole | 122 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 24 |
| Losartan Potassium | Losartan Potassium | 86 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 19 |
| Ketoconazole | Ketoconazole | 83 | 34 |
| Gabapentin | Gabapentin | 82 | 23 |
| Spironolactone | Spironolactone | 81 | 17 |
| Donepezil Hcl | Donepezil Hcl | 76 | suppressed |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 60 | 16 |
| Jardiance | Empagliflozin | 58 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 13 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Allopurinol | Allopurinol | 55 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 17 |
| Potassium Chloride | Potassium Chloride | 52 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 14 |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Cefdinir | Cefdinir | 38 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Furosemide | Furosemide | 31 | 11 |
| Meloxicam | Meloxicam | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,176.57 · 65 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, Bimzelx, CAPLYTA, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, HORIZANT, JOURNAVX, Kerendia, LEQVIO, Miro3D, ORTHOLOC 2 LAPIFUSE, OTEZLA, Ohtuvayre, Ozempic, PREVENA, Physio-Stim, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, URGOCLEAN AG, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VRAYLAR, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error